308 related articles for article (PubMed ID: 10825042)
21. [Toxic shock-like syndrome caused by streptococci].
van Dissel JT; Kullberg BJ; van der Meer JW
Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1452-5. PubMed ID: 10443259
[TBL] [Abstract][Full Text] [Related]
22. [High-dose immunoglobulin--life-saving in invasive group A streptococcal infection. Report of eleven cases with only one fatality].
Arnholm B; Lundqvist A; Strömberg A
Lakartidningen; 2004 Aug; 101(35):2642-4. PubMed ID: 15458217
[TBL] [Abstract][Full Text] [Related]
23. [Life-threatening puerperal sepsis caused by group A streptococci].
Helmig RB; Arpi M
Ugeskr Laeger; 2000 May; 162(20):2891-2. PubMed ID: 10860429
[TBL] [Abstract][Full Text] [Related]
24. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients.
Norrby-Teglund A; Low DE; McGeer A; Kotb M
Adv Exp Med Biol; 1997; 418():563-6. PubMed ID: 9331714
[No Abstract] [Full Text] [Related]
25. Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model.
Tarnutzer A; Andreoni F; Keller N; Zürcher C; Norrby-Teglund A; Schüpbach RA; Zinkernagel AS
Clin Microbiol Infect; 2019 Apr; 25(4):512.e7-512.e13. PubMed ID: 30025835
[TBL] [Abstract][Full Text] [Related]
26. Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult quest.
Valiquette L; Low DE; McGeer AJ
Clin Infect Dis; 2009 Nov; 49(9):1377-9. PubMed ID: 19788361
[No Abstract] [Full Text] [Related]
27. Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.
Parks T; Wilson C; Curtis N; Norrby-Teglund A; Sriskandan S
Clin Infect Dis; 2018 Oct; 67(9):1434-1436. PubMed ID: 29788397
[TBL] [Abstract][Full Text] [Related]
28. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis.
Laupland KB; Kirkpatrick AW; Delaney A
Crit Care Med; 2007 Dec; 35(12):2686-92. PubMed ID: 18074465
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections.
Carapetis JR; Jacoby P; Carville K; Ang SJ; Curtis N; Andrews R
Clin Infect Dis; 2014 Aug; 59(3):358-65. PubMed ID: 24785239
[TBL] [Abstract][Full Text] [Related]
30. Toxic shock syndrome: major advances in pathogenesis, but not treatment.
Low DE
Crit Care Clin; 2013 Jul; 29(3):651-75. PubMed ID: 23830657
[TBL] [Abstract][Full Text] [Related]
31. Toxic shock syndrome surveillance in UK children.
Adalat S; Dawson T; Hackett SJ; Clark JE;
Arch Dis Child; 2014 Dec; 99(12):1078-82. PubMed ID: 24790135
[TBL] [Abstract][Full Text] [Related]
32. Intravenous immunoglobulin therapy for toxic shock syndrome.
Barry W; Hudgins L; Donta ST; Pesanti EL
JAMA; 1992 Jun; 267(24):3315-6. PubMed ID: 1597914
[TBL] [Abstract][Full Text] [Related]
33. Streptococcal toxic shock syndrome: a physician tells the story of her survival.
Maytan M
Clin Infect Dis; 2000 Jun; 30(6):922-4. PubMed ID: 10880301
[No Abstract] [Full Text] [Related]
34. Group A streptococcal bacteremia: outcome and prognostic factors.
Vallalta Morales M; Soriano Navarro CJ; Salavert Lletí M; Montero Alonso M; Pérez Bellés C; López Aldeguer J; Otero MC; Gobernado Serrano M
Rev Esp Quimioter; 2006 Dec; 19(4):367-75. PubMed ID: 17235407
[TBL] [Abstract][Full Text] [Related]
35. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit.
El-Nawawy A; El-Kinany H; Hamdy El-Sayed M; Boshra N
J Trop Pediatr; 2005 Oct; 51(5):271-8. PubMed ID: 15917261
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Necrotizing Soft Tissue Infections: IVIG.
Madsen MB; Bergsten H; Norrby-Teglund A
Adv Exp Med Biol; 2020; 1294():105-125. PubMed ID: 33079366
[TBL] [Abstract][Full Text] [Related]
37. Comment on: Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation.
Rajagopalan G; Patel R; Kaveri SV; David CS
J Antimicrob Chemother; 2007 Jan; 59(1):157-9; author reply 159-60. PubMed ID: 17071954
[No Abstract] [Full Text] [Related]
38. [Neonatal toxic shock syndrome due to Streptococcus pyogenes: case report and literature review].
Díaz A M
Rev Chilena Infectol; 2007 Dec; 24(6):493-6. PubMed ID: 18180826
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of group A streptococcal bacteremia with comparison between children and adults.
Huang YC; Huang YC; Chiu CH; Chang LY; Leu HS; Lin TY
J Microbiol Immunol Infect; 2001 Sep; 34(3):195-200. PubMed ID: 11605811
[TBL] [Abstract][Full Text] [Related]
40. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
